<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>74</volume><submitter>Dos Anjos Cordeiro JM</submitter><funding>FAPEMIG</funding><funding>CAPES</funding><funding>Conselho Nacional de Desenvolvimento Cientifico e Tecnologico</funding><funding>Santa Cruz State University</funding><pubmed_abstract>Oxidative stress (OS) and endoplasmic reticulum stress (ERS) are at the genesis of placental disorders observed in preeclampsia, intrauterine growth restriction, and maternal hypothyroidism. In this regard, cationic manganese porphyrins (MnPs) comprise potent redox-active therapeutics of high antioxidant and anti-inflammatory potential, which have not been evaluated in metabolic gestational diseases yet. This study evaluated the therapeutic potential of two MnPs, [MnTE-2-PyP]&lt;sup>5+&lt;/sup> (MnP I) and [MnT(5-Br-3-E-Py)P]5+ (MnP II), in the fetal-placental dysfunction of hypothyroid rats. Hypothyroidism was induced by administration of 6-Propyl-2-thiouracil (PTU) and treatment with MnPs I and II 0.1 mg/kg/day started on the 8th day of gestation (DG). The fetal and placental development, and </pubmed_abstract><journal>Redox biology</journal><pagination>103238</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11225907</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Manganese porphyrin-based treatment improves fetal-placental development and protects against oxidative damage and NLRP3 inflammasome activation in a rat maternal hypothyroidism model.</pubmed_title><pmcid>PMC11225907</pmcid><pubmed_authors>Santos EO</pubmed_authors><pubmed_authors>de Jesus Nascimento AE</pubmed_authors><pubmed_authors>Mendonca LD</pubmed_authors><pubmed_authors>de Lavor MSL</pubmed_authors><pubmed_authors>Santos AS</pubmed_authors><pubmed_authors>Santos BR</pubmed_authors><pubmed_authors>Barbosa EM</pubmed_authors><pubmed_authors>Santos LC</pubmed_authors><pubmed_authors>de Macedo IO</pubmed_authors><pubmed_authors>Reboucas JS</pubmed_authors><pubmed_authors>Munhoz AD</pubmed_authors><pubmed_authors>Coura ETDS</pubmed_authors><pubmed_authors>Dos Anjos Cordeiro JM</pubmed_authors><pubmed_authors>Pinho CS</pubmed_authors><pubmed_authors>De-Freitas-Silva G</pubmed_authors><pubmed_authors>Rodrigues ME</pubmed_authors><pubmed_authors>Silva JF</pubmed_authors><pubmed_authors>Sarmento-Neto JF</pubmed_authors></additional><is_claimable>false</is_claimable><name>Manganese porphyrin-based treatment improves fetal-placental development and protects against oxidative damage and NLRP3 inflammasome activation in a rat maternal hypothyroidism model.</name><description>Oxidative stress (OS) and endoplasmic reticulum stress (ERS) are at the genesis of placental disorders observed in preeclampsia, intrauterine growth restriction, and maternal hypothyroidism. In this regard, cationic manganese porphyrins (MnPs) comprise potent redox-active therapeutics of high antioxidant and anti-inflammatory potential, which have not been evaluated in metabolic gestational diseases yet. This study evaluated the therapeutic potential of two MnPs, [MnTE-2-PyP]&lt;sup>5+&lt;/sup> (MnP I) and [MnT(5-Br-3-E-Py)P]5+ (MnP II), in the fetal-placental dysfunction of hypothyroid rats. Hypothyroidism was induced by administration of 6-Propyl-2-thiouracil (PTU) and treatment with MnPs I and II 0.1 mg/kg/day started on the 8th day of gestation (DG). The fetal and placental development, and </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Aug</publication><modification>2026-05-26T14:03:24.013Z</modification><creation>2025-04-06T11:37:19.001Z</creation></dates><accession>S-EPMC11225907</accession><cross_references><pubmed>38870780</pubmed><doi>10.1016/j.redox.2024.103238</doi></cross_references></HashMap>